Topiramate for the treatment of cocaine addiction

JAMA Psychiatry

Volumn 70, Issue 12, 2013, Pages 1338-1346

  Johnson, Bankole A ^a,b   Ait Daoud, Nassima ^a   Wang, Xin Qun ^a   Penberthy, J Kim ^a   Javors, Martin A ^c   Seneviratne, Chamindi ^a   Liu, Lei ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; COCAINE; GLUTAMATE RECEPTOR; PLACEBO; TOPIRAMATE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL RESEARCH; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONCENTRATION LOSS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG URINE LEVEL; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; MORNING DOSAGE; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PARESTHESIA; PATIENT COMPLIANCE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TASTE ACUITY; TREATMENT DURATION; UNITED STATES; URINALYSIS; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

EID: 84890093433     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.2295     Document Type: Article

References (66)

1. Rockhold RW. Glutamatergic involvement in psychomotor stimulant action. Prog Drug Res. 1998;50:155-192.
2. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol. 1998;54(6):679-720.
3. Kaddis FG, Uretsky NJ, Wallace LJ. DNQX in the nucleus accumbens inhibits cocaine-induced conditioned place preference. Brain Res. 1995;697 (1-2:76-82.
4. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13(5):177-184.
5. Kalivas PW, Churchill L, Klitenick MA. GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience. 1993;57(4):1047-1060.
6. Heimer L, Zahm DS, Churchill L, Kalivas PW, Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience. 1991;41(1):89-125.
7. Hemby SE, Johnson BA, Dworkin SI. Neurobiological basis of drug reinforcement. In: Johnson BA, Roache JD, eds. Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior. Philadelphia, PA: Lippincott-Raven; 1997:137-169.
8. David V, Durkin TP, Cazala P. Rewarding effects elicited by the microinjection of either AMPA or NMDA glutamatergic antagonists into the ventral tegmental area revealed by an intracranial self-administration paradigm in mice. Eur J Neurosci. 1998;10(4):1394-1402.
9. De Vries TJ, Schoffelmeer AN, Binnekade R, Mulder AH, Vanderschuren LJ. MK-801 reinstates drug-seeking behaviour in cocaine-trained rats. Neuroreport. 1998;9(4):637-640.
10. Cervo L, Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Res. 1995;673(2):242-250.
11. Karler R, Calder LD, Thai DK, Bedingfield JB. The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine. Pharmacol Biochem Behav. 1998;60(1):237-244.
12. Dewey SL, Chaurasia CS, Chen CE, et al. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse. 1997;25(4):393-398.
13. Peris J. Repeated cocaine injections decrease the function of striatal gamma-aminobutyric acid (A) receptors. J Pharmacol Exp Ther. 1996;276(3):1002-1008.
14. Cameron DL, Williams JT. Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J Neurosci. 1994;14(11, pt 1):6763-6767.
15. Dewey SL, Morgan AE, Ashby CR Jr, et al. A novel strategy for the treatment of cocaine addiction. Synapse. 1998;30(2):119-129.
16. Morgan AE, Dewey SL. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse. 1998;28(1):60-65.
17. Kushner SA, Dewey SL, Kornetsky C. Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology (Berl). 1997;133(4):383-388.
18. Schechter MD, Calcagnetti DJ. Continued trends in the conditioned place preference literature from 1992 to 1996, inclusive, with a cross-indexed bibliography. Neurosci Biobehav Rev. 1998;22(6):827-846.
19. Gerasimov MR, Schiffer WK, Gardner EL, et al. GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine. Eur J Pharmacol. 2001;414(2-3):205-209.
20. Witkin JM. Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci. 1993;53(24):PL405-PL410.
21. Schiffer WK, Gerasimov MR, Marsteller DA, et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse. 2001;42(3):196-198.
22. Bäckström P, Hyytiä P. Involvement of AMPA/kainate, NMDA, and mGlu5 receptors in the nucleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berl). 2007;192(4):571-580.
23. Uys JD, LaLumiere RT. Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurol Disord Drug Targets. 2008;7(5):482-491.
24. Pap A, Bradberry CW. Excitatory amino acid antagonists attenuate the effects of cocaine on extracellular dopamine in the nucleus accumbens. J Pharmacol Exp Ther. 1995;274(1):127-133.
25. Moghaddam B, Bolinao ML. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse. 1994;18(4):337-342.
26. Petroff OA, Hyder F, Mattson RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology. 1999;52(3):473-478.
27. Petroff OA, Hyder F, Rothman DL, Mattson RH. Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia. 2001;42(4):543-548.
28. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997;28(3):167-179.
29. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers: potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339-350.
30. Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41(suppl 1):S10-S16.
31. Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 2000;41(suppl 1):S45-S47.
32. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-1685.
33. Johnson BA, Rosenthal N, Capece JA, et al; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.
34. Elkashef A, Kahn R, Yu E, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial [published correction appears in Addiction. 2012;107(9): 1718]. Addiction. 2012;107(7):1297-1306.
35. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233-240.
36. Johnson BA, Roache JD, Ait-Daoud N, et al. Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking. Addict Biol. 2013;18(3):405-416.
37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. ed 4. Washington, DC: American Psychiatric Association; 1994.
38. First MB, Spitzer RL, Gibbon M, Williams J B W. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Dept, New York State Psychiatric Institute; 1994.
39. Mezinskis J, Dyrenforth S, Goldsmith RJ, Cohen M, Somoza E. Craving and withdrawal symptoms for various drugs of abuse. Psychiatr Ann. 1998;28:577-583.
40. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rev ed. Rockville, MD: National Institute of Mental Health; 1976. DHEW Publication No. 76-338 (ADM).
41. Tracy K, Baker S, LoCastro J, Mezinskis J, Simon S, Somoza E. The Substance Clinical Global Impression (SCGI) Scale: measuring global functioning in substance related clinical trials [abstract]. NIDA Res Monogr. 1999;180:169.
42. Maude-Griffin PM, Hohenstein JM, Humfleet GL, Reilly PM, Tusel DJ, Hall SM. Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: main and matching effects. J Consult Clin Psychol. 1998;66(5):832-837.
43. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758-1764.
44. Elkashef A, Fudala PJ, Gorgon L, et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend. 2006;85(3):191-197.
45. Preston KL, Silverman K, Schuster CR, Cone EJ. Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction. 1997;92(6):717-727.
46. Paliwal P, Hyman SM, Sinha R. Craving predicts time to cocaine relapse: further validation of the Now and Brief versions of the Cocaine Craving Questionnaire. Drug Alcohol Depend. 2008;93(3):252-259.
47. Elkashef A, Holmes TH, Bloch DA, et al. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction. 2005;100(suppl 1):91-101.
48. Kampman KM, Volpicelli JR, McGinnis DE, et al. Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav. 1998;23(4):449-461.
49. US Food and Drug Administration. Science and research: guidance documents (including information sheets) and notices. www.fda.gov/ScienceResearch/ SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/ default.htm. Accessed August 28, 2012.
50. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
51. Hollingshead AB, Redlich FC. Social Class and Mental Illness: A Community Study. New York, NY: John Wiley; 1958.
52. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293.
53. Haney M, Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology (Berl). 2008;199(3):403-419.
54. Sofuoglu M, Waters AJ, Mooney M, O'Malley SS. Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans. Pharmacol Biochem Behav. 2009;92(1):135-140.
55. Weiss RD, Griffin ML, Hufford C. Craving in hospitalized cocaine abusers as a predictor of outcome. Am J Drug Alcohol Abuse. 1995;21(3):289-301.
56. de Wit H. Laboratory-based assessment of alcohol craving in social drinkers. Addiction. 2000;95(suppl 2):S165-S169.
57. Gomer B, Wagner K, Frings L, et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav. 2007;10(3):486-494.
58. Loring DW, Williamson DJ, Meador KJ, Wiegand F, Hulihan J. Topiramate dose effects on cognition: a randomized double-blind study. Neurology. 2011;76(2):131-137.
59. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia. 2000;41(9):1167-1178.
60. Park S-P, Kwon S-H. Cognitive effects of antiepileptic drugs. J Clin Neurol. 2008;4(3):99-106.
61. Rose ME, Grant JE. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry. 2008;20(3):145-155.
62. Johnson BA, Roache JD, Ait-Daoud N, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend. 2006;84(3):256-263.
63. Johnson BA, Ait-Daoud N, Elkashef AM, et al; Methamphetamine Study Group. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol. 2008;11(1):1-14.
64. Johnson BA, DiClemente CC, Ait-Daoud N, Stoks SM. Brief Behavioral Compliance Enhancement Treatment (BBCET) manual. In: Johnson BA, Ruiz P, Galanter M, eds. Handbook of Clinical Alcoholism Treatment. Baltimore, MD: Lippincott Williams & Wilkins; 2003:282-301.
65. Fertig JB, Ryan ML, Falk DE, et al; NCIG 002 Study Group. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(8):1421-1430.
66. Rawson RA, McCann MJ, Flammino F, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006;101(2):267-274.